Our results indicated that a panel of E2F target gene signature, comprising of HN1, KIF4A, CDCA3, CDCA8 and SSRP1, is a reliable tool for predicting the overall survival of Hepatocellular carcinoma patients, and provided significant reference of clinical risk for Hepatocellular carcinoma patients. This evidence concerns the gene JPT1 and hepatocellular carcinoma.